Center for Nanomedicine and Department of Anaesthesiology, Brigham and Women's Hospital and Harvard Medical School, 75 Francis Street, Boston, Massachusetts 02115, USA.
Department of Micro and Nanotechnology, Technical University of Denmark, Produktionstorvet, Kgs. Lyngby, 2800, Denmark.
Nat Rev Nephrol. 2016 Dec;12(12):738-753. doi: 10.1038/nrneph.2016.156. Epub 2016 Oct 31.
Treatment and management of kidney disease currently presents an enormous global burden, and the application of nanotechnology principles to renal disease therapy, although still at an early stage, has profound transformative potential. The increasing translation of nanomedicines to the clinic, alongside research efforts in tissue regeneration and organ-on-a-chip investigations, are likely to provide novel solutions to treat kidney diseases. Our understanding of renal anatomy and of how the biological and physico-chemical properties of nanomedicines (the combination of a nanocarrier and a drug) influence their interactions with renal tissues has improved dramatically. Tailoring of nanomedicines in terms of kidney retention and binding to key membranes and cell populations associated with renal diseases is now possible and greatly enhances their localization, tolerability, and efficacy. This Review outlines nanomedicine characteristics central to improved targeting of renal cells and highlights the prospects, challenges, and opportunities of nanotechnology-mediated therapies for renal diseases.
肾脏疾病的治疗和管理目前在全球范围内带来了巨大的负担,而将纳米技术原理应用于肾脏疾病治疗虽然仍处于早期阶段,但具有深远的变革潜力。随着纳米药物不断向临床转化,以及组织再生和器官芯片研究方面的努力,很可能为治疗肾脏疾病提供新的解决方案。我们对肾脏解剖结构的理解,以及纳米药物(纳米载体和药物的组合)的生物学和物理化学性质如何影响它们与肾脏组织的相互作用的理解,已经取得了巨大的进展。现在可以根据纳米药物在肾脏中的保留情况和与肾脏疾病相关的关键膜和细胞群体的结合情况对其进行定制,从而极大地提高了它们的定位、耐受性和疗效。这篇综述概述了对肾脏细胞进行靶向治疗的纳米药物的特征,并强调了纳米技术介导的肾脏疾病治疗的前景、挑战和机遇。